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Abstract. The present study aimed to ascertain the signifi-
cance of topoisomerase II α (TOP2A) and minichromosome 
maintenance protein (MCM) 2 expression in anal carcinoma. 
A total of 75 anal lesions were retrieved from the files of 
the Department of Pathology of Barretos Cancer Hospital 
(Barretos, Brazil) in order to verify the human papillo-
mavirus (HPV) statuses of these lesions and characterize 
the immunohistochemical expression levels of TOP2A and 
MCM2 in anal carcinoma, as these are important markers 
for cervical HPV-induced lesions; their expression was also 
compared with respect to p16 and Ki-67. The vast majority 
of the cases tested positive for HPV16 (84%); 1 case tested 
positive for both HPV16 and HPV18. Positive HPV16 status 
was more frequent in early stages than in advanced stages 
(P=0.008). Positive immunohistochemical reactivity for 
MCM2 and TOP2A protein was observed in 71.6 and 100% 
of cases, respectively. Positive reactivity for p16 was signifi-
cantly associated (P=0.001) with histological grade, and 
was more commonly expressed in squamous cell carcinoma 
than adenocarcinomas. HPV16 was strongly associated with 
positive p16 protein expression (76.6%). However, the high 
expression of Ki-67 combined with the high expression of p16 
was predominantly observed in Stage III-IV cases. MCM2, 
TOP2A, p16 and Ki-67 exhibited intense positive staining in 
the anal lesions, indicating that these markers were signifi-
cantly and constantly expressed in anal carcinoma.
Introduction
Human papillomavirus (HPV) is thought to be the carcino-
genic agent responsible for all cases of cervical cancer, and 
for carcinomas of other anatomical sites, including anal carci-
nomas. Currently, >85% of anal carcinomas are thought to be 
associated with oncogenic HPV, and, among all high-risk HPV 
types, type 16 is recognized as the most common, with preva-
lence rates estimated at ~70% of all cases (1). In contrast to 
cervical carcinoma, the incidence of anal carcinoma is gradu-
ally increasing, accounting for ~2.2% of all gastrointestinal 
tract malignancies in the United States, with 6,230 cases newly 
diagnosed each year (2). Similar data have been also docu-
mented in other countries, such as Denmark (3). Populations 
at increased risk include women with cervical HPV-related 
neoplasia, immunosuppressed transplant patients and human 
immunodeficiency virus (HIV)-positive individuals. Risk 
factors for anal carcinoma acquisition also comprise history 
of smoking, history of condylomata (due to HPV exposition), 
and history of anal intercourse, indicating HPV infection in 
the anal canal (4). Notably, anal carcinoma is most frequent 
in men who have sex with men (MSM), who are ~20 times 
more likely than heterosexual men to develop the disease. 
Furthermore, MSM with HIV are at increased risk for anal 
cancer development (5). The estimated rate of anal carcinoma 
among HIV-positive persons is 174/100,000, as compared to 
an incidence of 2/100,000 among the HIV-negative popula-
tion. MSM represent ~75% of the population at risk for the 
development of anal carcinoma (6). 
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Experimental studies have revealed that the E7 gene of 
HPV16 is a major participant in anal carcinogenesis (7). Thus, 
HPV vaccination is expected to be useful for MSM and the 
HIV-positive population to avoid anal cancer development (6). 
Alternatively, screening for anal cancer in the HIV-positive 
population has been proposed; however, at present, the 
efficacy of available markers has not been satisfactorily veri-
fied (8). Despite this, the use of markers to improve diagnosis 
and prognosis in anal cancer screening is of interest as brush 
sampling of the anus represents a realistic, minimally invasive 
option for this proposal (9). 
In recent years, a number of different molecular markers 
have been tested with regard to optimization of the diagnosis 
of high-grade anal lesions (10). The assay most frequently 
investigated for this goal is immunohistochemical analysis 
of p16, which is widely used and can be used to successfully 
ascertain high-grade lesions in cytologically doubtful cervical 
HPV‑induced lesions (11). The sensitivity and specificity of 
p16 for the detection of high-grade lesions may be markedly 
improved with the addition of Ki-67, a cell cycle marker, in the 
immunostaining panel (12). Considering the histological and 
etiological similarities between cervical and anal carcinomas, 
it is unsurprising that these two markers yielded promising 
results when added to anal carcinoma analyses (13). Notably, 
Ki-67 was demonstrated to detect anal HPV-related alterations 
with a high sensitivity and specificity, and p16 positive reac-
tivity was found to be strongly associated with anal high-grade 
lesions (14). In cervical lesions, the expression of p16 and Ki-67 
increases in parallel according to the degree of severity of the 
lesions (15). Additionally, combined p16 and Ki-67 immunos-
taining reduces the diagnostic variability among professionals 
and improves the detection of anal high-grade lesions (16).
Other adjunct markers have been added in different 
panels to improve anal lesions diagnosis. Among them is the 
minichromosome maintenance proteins (MCMs), a protein 
family with six major isoforms (MCM2-7) that are critical 
in restricting DNA synthesis to once per cell cycle, and also 
regulating DNA elongation (17). Dysregulated expression of 
MCM family proteins has been observed in a plethora of solid 
tumors, including anal cancer, and the results encourage its use 
to discriminate high-grade lesions of the anus (17). In cervical 
carcinoma, the usefulness of MCMs (MCM2 and MCM7) has 
also been documented, and their performances in the dectec-
tion of high-grade lesions were comparable to that of p16 and 
Ki-67 expression (18). 
Similarly, topoisomerase II α (TOP2A) is frequently 
overexpressed in cervical neoplasia. This nuclear enzyme acts 
to relax the supercoiled DNA during cell replication and is 
involved in chromosome condensation, and it is critical for the 
normal segregation of daughter chromosomes at the end of cell 
division (18). Notably, TOP2A overexpression is associated 
with the progression from cervical intraepithelial neoplasia 
grade 2 to a more advanced cervical lesion (18). Currently, an 
immunohistochemical biomarker named BD ProEx C (BD 
Diagnostics, Burlington, NC, USA), combining MCM2 and 
TOP2A antibodies, is available and has been used to identify 
cervical high-grade lesions (18). Despite the importance of 
MCM2 and TOP2A in the investigation of cervical carci-
noma, to the best of our knowledge, these markers have not 
been studied in anal carcinoma. Accordingly, the present study 
investigated the expression of MCM2 and TOP2A in 75 cases 
of anal carcinoma in order to characterize the expression of 
these markers with regard to the diagnostic and prognostic 
evaluation of anal cancer in routine practice, and compared 
their expression with that of p16 and Ki-67.
Materials and methods
Study design. A total of 75 consecutive cases of anal high-grade 
lesions were retrieved from the files of the Department of 
Pathology of Barretos Cancer Hospital (Barretos, Brazil) 
between January 2000 and December 2010. Sociodemo-
graphic and clinicopathological data were recovered from the 
patients' records. Histopathological revision of the slides was 
performed by one qualified pathologist in the group (C.S.N.). 
New sections from the paraffin‑blocks of the tumors were cut 
for immunohistochemical analysis and HPV DNA test.
Ethics. The study protocol was approved by the local Ethics 
Committee of Barretos Cancer Hospital, and the authors 
declare no conflict of interest.
DNA extraction. DNA was extracted from fresh material using 
a QIAamp DNA Mini Kit (Qiagen Biotecnologia Brasil, Ltda., 
São Paulo, Brazil), according to the manufacturer's instruc-
tions, and from formalin‑fixed paraffin‑embedded tissue using 
a QIAamp DNA Micro Kit (Qiagen Biotecnologia Brasil, 
Ltda.), also according to the manufacturer's instructions.
HPV identification followed protocols published previ-
ously (19). The main steps are described below.
E7 HPV16 type‑specific quantitative polymerase chain 
reation (qPCR). Type‑specific TaqMan‑based qPCR targeting 
HPV16 E7 used HPV16 E7 type‑specific (20) oligonucleotide 
primers (forward, 5'-GAT GAA ATA GAT GGT CCAGC-3 ', and 
reverse, 5'-GCT TTG TAC GCA CAA CCG AAGC-3') and a 
probe (5'-FAM-CAA GCA GAA CCG GAC AG-MGB-NFQ), in 
a final reaction volume of 25 µl. Each qPCR mixture contained 
1X TaqMan Master Mix (Applied Biosystems; Thermo Fisher 
Scientific, Inc., Foster City, CA, USA), 400 nM of each forward 
and reverse primer, 200 nM of fluorogenic TaqMan probe and 
5 µl of extracted DNA. The amplification conditions were as 
follows: 50˚C for 2 min; 95˚C for 10 min; and 40 cycles of 
95˚C for 15 sec, 55˚C for 1 min and 60˚C for 1 min. qPCR was 
performed in an ABI 7300 Real-Time PCR System (Applied 
Biosystems; Thermo Fisher Scientific, Inc.). Each qPCR 
run included the following controls: i) SiHa cell line DNA 
(harboring 1-2 copies/cell of HPV16), and ii) water as a nega-
tive control. All samples and controls were run in duplicate.
E7 HPV‑18 type‑specific qPCR. Type‑specific TaqMan‑based 
qPCR targeting HPV18 E7 was performed using HPV18 
E7 type-specific (20) oligonucleotide primers (forward, 
5'-AAG AAA ACG ATG AAA TAG ATGGA-3', and reverse, 
5' GGC TTC CAC CTT ACA ACACA-3') primers and probe 
(5'-VIC-AAT CAT CAA CAT TTA CCA GCC -MGB-NFQ-3'), 
in a final reaction volume of 25 µl. Each qPCR mixture 
contained 1X TaqMan Master Mix, 400 nM of each forward 
and reverse primer, 400 nM of fluorogenic TaqMan probe and 
5 µl of extracted DNA. The amplification conditions were as 
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follows: 50˚C for 2 min; 95˚C for 10 min; and 40 cycles of 
95˚C for 15 sec, 50˚C for 1 min and 60˚C for 1 min. qPCR 
was performed in an ABI 7300 Real-Time PCR System 
and included the following controls: i) HeLa cell line DNA 
(harboring 20 copies/cell of HPV18), and ii) water as negative 
control. All samples and controls were run in duplicate.
Human β‑globin PCR. Samples that were determined to be 
negative for HPV16 and HPV18 were submitted to a PCR 
analysis capable of detecting a 110-bp fragment of the human 
β-globin gene, in order to assess the DNA quality and integrity. 
β-globin PCR was conducted using 20 mM Tris-HCl (pH 8.4), 
50 mM KCl, 4 mM MgCl2, 200 µM dNTP mix (all from Invit-
rogen; Thermo Fisher Scientific, Inc.), 200 nM forward primer 
PCO3 (5'-ACA CAA CTG TGT TCA CTAGC-3'), 200 nM reverse 
primer PCO4 (5'-CAA CTT CAT CCA CGT TCACC-3') (21), 
1.25 U Platinum® Taq DNA Polymerase (Invitrogen; Thermo 
Fisher Scientific, Inc.), 5.7% glycerol, 0.25 µg/µl of Cresol 
Red, 5 µl of extracted DNA, and water, to a final volume 25 µl. 
The amplification conditions were as follows: 94˚C for 5 min; 
followed by 40 cycles of 94˚C for 1 min, 55˚C for 1 min and 
72˚C for 1 min; and a final extension phase of 72˚C for 10 min. 
PCR was performed in a Mastercycler Gradient (Eppendorf, 
Hamburg, Germany).
Immunohistochemical reactions. Histological sections of 4 µm 
thickness were deparaffinized in an oven at 80˚C for 30 min. 
Immunostaining was conducted in an Ultra Benchmark Auto-
stainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) 
using the following antibodies under specific conditions: Ki‑67 
(cat. no. M3060; Spring Bioscience Corporation, Pleasanton, 
CA, USA; dilution, 1:600), with 60 min antigen retrieval using 
CC1 (Ventana Medical Systems, Inc.) followed by incubation 
for 32 min; p16 (CINtec®; Ventana Medical Systems, Inc.; 
prediluted), with 30 min antigen retrieval using CC1 followed 
by incubation for 32 min; TOP2A (cat. no. ab52934; Abcam, 
Cambridge, MA, USA; dilution, 1:200), with 60 min antigen 
retrieval using CC1 (Ventana Medical Systems, Inc.) and incu-
bation for 32 min; MCM2 (cat. no. ab6153; Abcam; dilution, 
Table II. Characterization of the study population according to 
immunohistochemical information (immunostaining of p16, 
Ki-67, MCM and TOP2A) and HPV infection.
Variable  n %
p16 immunoexpression (n=72)
  Negative 17 23.6
  Positive 55 76.4
Ki-67 immunoexpression (n=73)  
  1+   3   4.1
  2+   2   2.7
  3+   9 12.3
  4+ 59 80.8
MCM immunoexpression (n=74)  
  Negative 21 28.4
  +1 16 21.6
  +2 13 17.6
  +3 24 32.4
TOP2A immunoexpression (n=67)  
  1+   8 11.9
  2+ 42 62.7
  3+ 17 25.4
HPV16 detection (n=75)  
  Negative 12 16.0
  Positive 63 84.0
HPV18 detection (n=75)  
  Negative 74 98.7
  Positivea   1   1.3
aThe case with HPV18 had co-infection with HPV16. MCM, 
minichromosome maintenance protein; TOP2A, topoisomerase II α; 
HPV, human papillomavirus.
 
Table I. Characterization of the study population according 
to demographic information, clinical and histopathological 
findings.
Variable  n %
Age, years (n=75)  
  <40   9 12.0
  40-59 41 54.7
  ≥60 25 33.3
Gender (n=75)  
  Female 49 65.3
  Male 26 34.7
Clinical stage (n=70)  
  Stage 0   7 10.0
  Stage I   3   4.3
  Stage II 33 47.1
  Stage III 19 27.1
  Stage IV   8 11.4
Histopathological type (n=74)  
  Squamous (invasive and in situ) 55 74.3
  Adenocarcinoma 19 25.7
Histological grade (n=40) 
  Grade 1   9 20.0
  Grade 2 18 40.0
  Grade 3 18 40.0
Regional recurrence (n=75)
  No 71 94.7
  Yes   4   5.3
Distant metastasis (n=75) 
  No 62 82.7
  Yes 13 17.3
Status (n=75)  
  Alive without disease 39 52.0
  Alive with disease   7   9.3
  Deceased (from cancer) 25 33.3
  Deceased (from other causes)   4   5.3
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1:50), with 60 min antigen retrieval using CC1 (Ventana 
Medical Systems, Inc.) and incubation for 60 min.
Immunohistochemical quantification. The p16 reaction was 
categorized as positive if nuclear and/or cytoplasmic immu-
nostaining was detected. Ki-67, MCM2 and TOP2A were 
considered positive only if brown nuclear staining was clearly 
observed. The scoring of positive reactions followed that of a 
previous report (22), with slight modifications: Negative (0); 
faintly positive (+), 1-10% positively stained cells; sporadic 
(++), 11-50% positively stained cells; intermediate (+++), 
51-75% positively stained cells; and diffuse (++++), >75% 
positively stained cells.
For statistical calculations, variables were clustered as 
follows: p16 and MCM2 were scored as positive or negative 
reactions; Ki-67 and TOP2A expression levels were scored 
as 1+/2+/3+/4+ and 1+/2+/3+, respectively (TOP2A posi-
tive reactions did not reach 4+ in any of the cases tested). 
The tumoral stages were dichotomously classified as 0, I 
and II and III and IV; histological grades were divided into 
grades 1-2, and grade 3; and the presence of distant metas-
tasis was designated as no or yes.
Table III. Five-year overall survival probabilities according to the study variables.
Variable n 5-year overall survival rate (%) P-value
Age, years (n=75)   0.052
  <40   9 63.5 
  40-59 41 74.8 
  ≥60 25 48.0 
Gender  (n=75)   0.556
  Female 49 66.9 
  Male 26 60.1 
Clinical stage (n=70)   0.012
  Stage 0-II 43 73.4 
  Stage III-IV 27 47.4 
Histopathological type (n=74)   <0.001
  Squamous (invasive and in situ) 55 74.0 
  Adenocarcinoma 19 35.1 
Treatment (n=75)   0.003
  Chemotherapy + radiotherapy 40 74.8 
  Chemotherapy + radiotherapy + surgery 16 73.4 
  Other 19 34.7 
Oncological response, QT/RT (n=69)   <0.001
  Complete 36 91.2 
  Incomplete/progression 33 28.1 
p16 immunoexpression (n=72)   0.200
  Negative 17 52.3 
  Positive 55 68.6 
Ki-67 immunoexpression (n=73)   0.648
  1+/2+   5 80.0 
  3+/4+ 68 64.2 
MCM immunoexpression (n=74)   0.114
  0/1+ 37 55.1 
  1+/2+ 37 72.7 
TOP2A immunoexpression (n=67)   0.548
  1+   8 72.9 
  2+/3+ 59 58.9 
HPV16 detection (n=75)   0.137
  Negative 12 48.6 
  Positive 63 67.6 
The survival analysis for HPV18 variable could not be performed as there was only 1 case. Data were compared using Student's t-tests. MCM, 
minichromosome maintenance protein; TOP2A, topoisomerase II α; HPV, human papillomavirus.
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Statistical analysis. The statistical data were analyzed with 
SPSS for Windows® version 20.0 (IBM SPSS, Armonk, NY, 
USA). Data were compared using Student's t-tests or Fisher's 
exact test. Prevalence rates were compared by means of a ‘z’ 
approximation in the SPSS package. Confidence intervals 
were also calculated. The significance level was set at 5%.
Results
General data. The patients comprised 49 females (65.3%) and 
26 males (34.7%); 63 were Caucasians (84.0%) and 12 patients 
were of African descent (16.0%). The mean age [± standard 
deviation (SD)] was 55.9±13.56 years. The follow-up periods 
among the patients varied from 1 to 123 months (mean, 39.93; 
median, 33.50).
The majority of the patients (n=38, 52.1%) declared that 
they were married (with a long/stable relationship of several 
years), 18 (24.7%) were single, 8 (11.0%) were divorced and 
9 (12.3%) were widows/widowers. The vast majority of the 
patients (n=53) had only basic school education, and 12 (16.9%) 
declared that they were illiterate.
Clinicopathological data. In the present study, a history of 
tobacco use was not significantly associated with anal cancer: 
33 (47.1%) had no history of tobacco smoking, 30 (40.0%) 
were current frequent tobacco smokers, and 7 (10.0%) reported 
that they had smoked tobacco in the past. Familial history of 
cancer was noted for 20 (27.0%) patients. The characterization 
of the study population according to the demographic informa-
tion, and clinical and histopathological findings, is depicted in 
Table I. Table II shows the frequencies of immunohistochemical 
reactivity for p16, Ki-67, MCM and TOP2a, and HPV infec-
tion; notably, HPV18 was simultaneously positive with HPV16 
in only 1 case. Table III shows the correlation of 5-year overall 
survival rates according to the other variables of the study. As 
expected, patients in stages 0-II had a greater 5-year overall 
survival rate compared with stages III-IV (P=0.012); the 
group with a complete oncological response also had a greater 
Table IV. Distribution of patient data according to histological type.
Variable Squamous/HSIL, n (%) Adenocarcinoma, n (%) P-value
Age, years (n=74)     0.008
  <40 5 (9.1)   4 (21.1) 
  40-59 36 (65.5)   5 (26.3) 
  ≥60 14 (25.5) 10 (52.6) 
Gender (n=74)     0.579
  Female  37 (67.3) 11 (57.9) 
  Male 18 (32.7)   8 (42.1) 
Clinical stage (n=69)     0.150
  Stage 0-I 34 (66.7)   8 (44.4) 
  Stage II-IV 17 (33.3) 10 (55.6) 
p16 (n=71)   <0.001
  Negative   6 (11.3) 10 (55.6) 
  Positive 47 (88.7)   8 (44.4) 
Ki-67 (n=73)     0.591
  1+/2+ 3 (5.5)   2 (11.1) 
  3+/4+ 52 (94.5) 16 (88.9) 
  <4+   9 (16.4)   5 (27.8)   0.312
  ≥4+ 46 (83.6) 13 (72.2) 
MCM (n=74)   <0.001
  0/1+ 20 (36.4) 17 (89.5) 
  2+/3+ 35 (63.6)   2 (10.5) 
TOP2A (n=66)     0.664
  1+   6 (12.5) 1 (5.6) 
  2+/3+ 42 (87.5) 17 (94.4) 
HPV16 detection (n=74)   0.276
  Negative   7 (12.7)   5 (26.3) 
  Positive 48 (87.3) 14 (73.7) 
It was not possible to analyze the association between histological type and HPV18 status as there was only 1 case that waspositive for HPV18. 
P-values were calculated by Fisher's exact test. HSIL, high-grade squamous intraepithelial lesion; MCM, minichromosome maintenance 
protein; TOP2A, topoisomerase II α; HPV, human papillomavirus.
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survival rate compared with those showing an incomplete 
response/progression (P=0.003). The expression levels of none 
of the proteins studied correlated significantly with overall 
survival rates.
Analysis of the histological types of anal carcinomas 
among the included cases revealed that the majority of cases 
were squamous cell carcinomas (P=0.008) among patients of 
all ages (Table IV). In addition, squamous cell carcinoma was 
the histological type that was most frequently associated with 
p16 and MCM2 positive immunoreactivity (both P<0.001). The 
histological grade was significantly associated with negative p16 
expression (P=0.001; data not shown), as p16 was not expressed 
in grade 3 tumors. Notably, TOP2A expression was associated 
with the absence of metastasis (P=0.008; data not shown).
The distribution of the variables according to the clinical 
stage is depicted in Table V. HPV detection was positive in the 
vast majority of cases, but was proportionally more prevalent 
(P=0.008) in cases of stages 0-II (40 cases, 93.0%) than in 
stages III-IV (18 cases, 66.7%).
Discussion
The current study presents notable findings regarding the 
regulation of HPV-induced tumors of the anus. Firstly, HPV 
was detected in squamous cell carcinomas, adenocarcinomas 
and high-grade squamous intraepithelial lesions (HSIL). The 
present study investigated only the two major types of high-risk 
HPV that are associated with anal carcinoma: HPV16 and 
HPV18. Only 1 case tested positive for HPV18, which limited 
any discussion regarding the importance of HPV18 in anal 
lesions in comparison with HPV16.
HPV-induced tumors are frequently associated with p16 
overexpression, which was confirmed in the present series of 
patients. However, the aggressiveness of these malignancies 
did not differ significantly among the tumor stages or in tumors 
with or without metastasis. Notably, negative p16 expression 
was not observed in grade 3 tumors. In previous studies, p16 
expression was observed in both the less aggressive altera-
tions and the more aggressive anal lesions (10,13). Evidence 
on p16 expression is controversial in the literature. The 
widespread positive immunoreactivity of p16 in anal cancer 
tumors of varying histological grades and clinical stages, and 
in tumors with or without distant metastasis, was suggested 
to demonstrate the limited usefulness of p16 as a prognostic 
marker (23). Longacre et al (23) suggested that p16 was more 
likely to be useful in distinguishing hyperplastic and atypical 
metaplastic squamous epithelium from dysplastic conditions. 
However, Serup-Hansen et al (24) demonstrated recently that 
Table V. Distribution of the variables according to the clinical stage.
Variable Stage 0-II, n (%) Stage III-IV, n (%) P-value
Age, years (n=66)   0.733
  <40   5 (11.6)   4 (14.8) 
  40-59 23 (58.1) 13 (48.1) 
  ≥60 13 (30.2) 10 (37.0) 
Gender (n=66)   0.306
  Female  30 (69.8) 15 (55.6) 
  Male 13 (30.2) 12 (44.4) 
p16 (n=63)   0.251
  Negative   8 (19.0)   8 (32.0) 
  Positive 34 (81.0) 17 (68.0) 
Ki-67 (n=64)   0.642
  1+/2+ 4 (9.5) 1 (3.8) 
  3+/4+ 38 (90.5) 25 (96.2) 
  <4+ 11 (26.2)   3 (11.5) 0.219
  ≥4+ 31 (73.8) 23 (88.5) 
MCM (n=65)   0.805
  0/1+ 21 (50.0) 15 (55.6) 
  2+/3+ 21 (50.0) 12 (44.4) 
TOP2A (n=60)   0.125
  1+   7 (18.9) 1 (3.8) 
  2+/3+ 30 (81.1) 25 (96.2) 
HPV16 detection (n=66)   0.008
  Negative 3 (7.0)   9 (33.3) 
  Positive 40 (93.0) 18 (66.7) 
It was not possible to analyze the association between histological type and HPV18 status as there was only 1 case positive for HPV18. P-values 
were calculated by Fisher's exact test. MCM, minichromosome maintenance protein; TOP2A, topoisomerase II α; HPV, human papillomavirus.
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p16 positivity is an independent prognostic factor for overall 
survival and disease‑specific survival in anal carcinoma of 
stages I-III. 
In the present study, Ki-67 was highly expressed (score 
+4) in the majority of cases, which indicated that these anal 
tumors were highly proliferative lesions; however, tumors with 
high proliferation rates did not differ from less proliferative 
tumors in terms of clinical behavior, as Ki-67 was expressed 
in tumors of different stages and all histological grades. The 
association between Ki-67 and p16 positive expression was 
previously reported, revealing a parallel increase in expression 
of the two markers according to the aggressiveness of cervical 
lesions (15). The anal lesions assessed in the current study 
were all of a high-grade, which may explain the augmented 
indexes of proliferation demonstrated by Ki-67 immunoreac-
tivity. Previously, Ki-67 was reported to be increased in anal 
lesions that were positive for HPV, as compared with normal 
healthy anal tissues, although tissue samples from sites of anal 
inflammation with reactive changes also exhibited increased 
Ki‑67 values. However, p16 has been recognized as a specific 
biomarker for the presence of HPV in anal tissue, and has been 
associated with high-grade lesions (25).
The primary goal of the current study was to characterize 
and identify whether TOP2A and MCM2 may be useful as 
prognostic parameters in anal cancers, as they are for cervical 
carcinomas, particularly when assessed in association with the 
analysis of the p16 expression (26). In addition, the combined 
assessment of TOP2A and MCM2 expression provides a lower 
false positive rate in the diagnosis of malignant intraepithelial 
lesions, as compared with other currently used biological 
markers (27). In the present study, TOP2A was demonstrated 
to have an important role in anal carcinoma, since it exhibited 
moderate-to-strong positive reactivity in all cases; however, 
no statistical association was observed with regard to tumor 
aggressiveness. TOP2A in anal carcinoma was partially 
confirmed as all cases studied exhibited moderate to strong 
positive reactivity for this marker; however, no statistical 
association was observed with regard to tumor aggressiveness. 
Positive MCM2 reactivity was observed in almost 80% of the 
cases, which suggests that MCM2 is important in the progres-
sion of anal carcinoma. However, as for TOP2A, no correlation 
was observed with the clinicopathological parameters due to 
the persistent distribution of this marker.
Notably, the results herein have demonstrated that all the 
immunohistochemical markers were highly expressed in 
~80% of the cases, which indicates that anal carcinoma has 
a significant potential for proliferation. Additionally, these 
markers appear to have some association with HPV status, 
since 84% of cases tested positive for HPV16. HPV16 is highly 
prevalent in anal cancer, reaching 90% in some studies, and is 
significantly associated with high‑risk anal lesions and cancer 
progression (28).
The present series failed to establish any associations with 
respect to the HIV status in these patients; as a retrospective 
study, data regarding HIV statuses were unavailable for many 
patients. Currently, HIV testing is mandatory in routine clinical 
practice at our center, but was not in the past. For this reason, 
this parameter was not assessed. HIV patients, predominantly 
MSM, have an increased risk for anal cancer development, and 
the synergism with HPV is assumed to be a causative factor for 
anal carcinoma pathogenesis (29). Further studies considering 
HIV status may reveal differences among the markers tested 
and HPV status, with respect to prognostic impact.
In conclusion, the present study demonstrated that the eval-
uated biomarkers were significantly and constantly expressed 
in anal carcinoma and may be used in combination to evaluate 
the prognosis of anal cancer. 
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